RASAGILINE MESYLATE Drug Patent Profile
✉ Email this page to a colleague
When do Rasagiline Mesylate patents expire, and when can generic versions of Rasagiline Mesylate launch?
Rasagiline Mesylate is a drug marketed by Alkem Labs Ltd, Apotex Inc, Aurobindo Pharma Usa, Carnegie, Chartwell Rx, Indoco, Micro Labs, Orbion Pharms, and Watson Labs Inc. and is included in nine NDAs.
The generic ingredient in RASAGILINE MESYLATE is rasagiline mesylate. There are eighteen drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the rasagiline mesylate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Rasagiline Mesylate
A generic version of RASAGILINE MESYLATE was approved as rasagiline mesylate by ORBION PHARMS on March 15th, 2016.
Summary for RASAGILINE MESYLATE
| US Patents: | 0 |
| Applicants: | 9 |
| NDAs: | 9 |
| Finished Product Suppliers / Packagers: | 5 |
| Raw Ingredient (Bulk) Api Vendors: | 113 |
| Clinical Trials: | 14 |
| Patent Applications: | 197 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for RASAGILINE MESYLATE |
| DailyMed Link: | RASAGILINE MESYLATE at DailyMed |
Recent Clinical Trials for RASAGILINE MESYLATE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Teva Pharmaceutical Industries | Phase 1 |
| Teva Branded Pharmaceutical Products R&D, Inc. | Phase 1 |
| Teva Pharmaceutical Industries | Phase 4 |
Pharmacology for RASAGILINE MESYLATE
| Drug Class | Monoamine Oxidase Inhibitor |
| Mechanism of Action | Monoamine Oxidase Inhibitors |
Anatomical Therapeutic Chemical (ATC) Classes for RASAGILINE MESYLATE
US Patents and Regulatory Information for RASAGILINE MESYLATE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alkem Labs Ltd | RASAGILINE MESYLATE | rasagiline mesylate | TABLET;ORAL | 201889-001 | Oct 30, 2017 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Watson Labs Inc | RASAGILINE MESYLATE | rasagiline mesylate | TABLET;ORAL | 201823-002 | Jul 1, 2013 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Carnegie | RASAGILINE MESYLATE | rasagiline mesylate | TABLET;ORAL | 201942-001 | Nov 18, 2021 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
